Magnetic nanoparticles for tumor imaging and therapy: A so-called theranostic system

Pharmaceutical Research

Volumn 30, Issue 10, 2013, Pages 2445-2458

  He, Huining ^a,f   David, Allan ^b   Chertok, Beata ^b   Cole, Adam ^b   Lee, Kyuri ^b   Zhang, Jian ^b   Wang, Jianxin ^c,d   Huang, Yongzhuo ^c,d,e   Yang, Victor C ^b,f  

^a TIANJIN UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

^c FUDAN UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^e SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^f TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

brain tumor cancer; cell penetrating peptide; magnetic nanoparticles; theranostic system; tumor imaging and therapy

Indexed keywords

BETA GALACTOSIDASE; CARMUSTINE; CELL PENETRATING PEPTIDE; MAGNETIC IRON OXIDE NANOPARTICLE; MAGNETIC NANOPARTICLE; PRODRUG; PROTAMINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; BRAIN TUMOR; CANCER CONTROL; CANCER THERAPY; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; GLIOMA; HUMAN; MACROMOLECULE; MAGNETIC FIELD; NANOPHARMACEUTICS; NANOTOXICOLOGY; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES;

EID: 84883871656     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-0982-y     Document Type: Review

References (69)

1. National Cancer Institute at the U.S. National institute of health webpage. Available from: http://www.cancer.gov.
2. The children's brain tumor foundation webpage. Available from: http://www.cbtf.org/medical.b.html.
3. The brain tumor society webpage. Available from: http://www.tbts.org.
4. Grieg NH, Ries LG, Yancik R, Rapoport SI. Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst. 1990;82(20):1621-4.
5. Black PM. Brain tumors. New Engl J Med. 1991;324(21):1471-6.
6. Mokri B. The monro-kellie hypothesis. Neurology. 2001;56(12):1746-8.
7. Gutman RL, Peacock G, Lu DR. Targeted drug delivery for brain cancer treatment. J Control Release. 2000;65(1-2):31-41.
8. Srinivasan R. Review of brain and brain cancer treatment. Int J Pharm Bio Sci. 2011;2(1):468-77.
9. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39(6):789-96.
10. Nishio S, Morioka T, Fukui M. Radiation injury of the brain. Crit Rev Neurosurg. 1997;7(6):408-15.
11. New P. Radiation injury to the nervous system. Curr Opin Neurol. 2001;14(6):725-34.
12. Danoff BF, Cowchock FS, Marquette C, Mulgrew L, Kramer S. Assessment of the long-term effects of primary radiation. Therapy for brain tumors in children. Cancer. 1982;49(8):1580-6.
13. Hösli P, Sappino AP, de Tribolet N, Dietrich PY. Malignant glioma: Should chemotherapy be overthrown by experimental treatments? Ann Oncol. 1998;9(6):589-600.
14. Huynh GH, Deen DF, Szoka Jr FC. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release. 2006;110(2):236-59.
15. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3(2):90-105.
16. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. Cns Drugs. 2009;23(1):35-58.
17. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov. 2004;3(5):430-46.
18. Pastan I, Chaudhary V, FitzGerald DJ. Recombinant toxins as novel therapeutic agents. Annu Rev Biochem. 1992;61(1):331-54.
19. Angelastro JM, Canoll PD, Kuo J, Weicker M, Costa A, Bruce JN, et al. Selective destruction of glioblastoma cells by interference with the activity or expression of atf5. Oncogene. 2005;25(6):907-16.
20. Chang L-C, Lee H-F, Yang Z, Yang V. Low molecular weight protamine (lmwp) as nontoxic heparin/low molecular weight heparin antidote (i): preparation and characterization. AAPS J. 2001;3(3):7-14.
21. Chang L-C, Liang J, Lee H-F, Lee L, Yang V. Low molecular weight protamine (lmwp) as nontoxic heparin/low molecular weight heparin antidote (ii): in vitro evaluation of efficacy and toxicity. AAPS J. 2001;3(3):15-23.
22. Chang L-C, Wrobleski S, Wakefield T, Lee L, Yang V. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (iii): preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS J. 2001;3(3):24-31.
23. Park YJ, Chang L-C, Liang JF, Moon C, Chung C-P, Yang VC. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (lmwp), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J. 2005;19(11):1555-7.
24. Byun Y, Singh VK, Yang VC. Low molecular weight protamine: a potential nontoxic heparin antagonist. Thromb Res. 1999;94(1):53-61.
25. Liang JF, Zhen L, Chang LC, Yang VC. A less toxic heparin antagonist - low molecular weight protamine. Biochem Mosc. 2003;68(1):116-20.
26. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci. 1994;91(2):664-8.
27. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem. 2002;277(4):2437-43.
28. Chertok B, David AE, Yang VC. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release. 2011;155(3):393-9.
29. Protamine sulfate. In: Ahfs drug information. Bethesda: American Hospital Formulary Service; 2001. p. 1408-9.
30. Kwon YM, Li Y, Naik S, Liang JF, Huang Y, Park YJ, et al. The attempts delivery systems for macromolecular drugs. Expert Opin Drug Deliv. 2008;5(11):1255-66.
31. Strausbaugh LJ. Intracarotid infusions of protamine sulfate disrupt the blood-brain barrier of rabbits. Brain Res. 1987;409(2):221-6.
32. Chertok B, Moffat BA, David AE, Yu F, Bergemann C, Ross BD, et al. Iron oxide nanoparticles as a drug delivery vehicle for mri monitored magnetic targeting of brain tumors. Biomaterials. 2008;29(4):487-96.
33. Lee Y, Mo H, Koo H, Park J-Y, Cho MY, Jin G-w, et al. Visualization of the degradation of a disulfide polymer, linear poly(ethylenimine sulfide), for gene delivery. Bioconjug Chem. 2006;18(1):13-8.
34. Oupický D, Parker AL, Seymour LW. Laterally stabilized complexes of DNA with linear reducible polycations: strategy for triggered intracellular activation of DNA delivery vectors. J Am Chem Soc. 2001;124(1):8-9.
35. Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res. 2006;12(22):6677-86.
36. Chertok B, David AE, Yang VC. Delivery of functional proteins to brain tumor using mri-monitored, magnetically-targeted nanoparticles. J Control Release. 2008;132(3):e61-2.
37. Gamarra LF, Pontuschka WM, Amaro Jr E, Costa-Filho AJ, Brito GES, Vieira ED, et al. Kinetics of elimination and distribution in blood and liver of biocompatible ferrofluids based on fe3o4 nanoparticles: an epr and xrf study. Mater Sci Eng C Bio Syst. 2008;28(4):519-25.
38. Ślawska-Waniewska A, Mosiniewicz-Szablewska E, Nedelko N, Gała̧zka-Friedman J, Friedman A. Magnetic studies of iron-entities in human tissues. J Magn Magn Mater. 2004;272-6. Part 3(0):2417-2419.
39. Chertok B, Cole AJ, David AE, Yang VC. Comparison of electron spin resonance spectroscopy and inductively-coupled plasma optical emission spectroscopy for biodistribution analysis of iron-oxide nanoparticles. Mol Pharm. 2010;7(2):375-85.
40. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on mr images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging. 1999;9(2):228-32.
41. Kim T, Shima M. Reduced magnetization in magnetic oxide nanoparticles. J Appl Phys. 2007;101(9):09M516.
42. Papisov MI, Bogdanov Jr A, Schaffer B, Nossiff N, Shen T, Weissleder R, et al. Colloidal magnetic resonance contrast agents: effect of particle surface on biodistribution. J Magn Magn Mater. 1993;122(1-3):383-6.
43. Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 1996;56(20):4694-701.
44. Yoshizaki K, Adachi K, Kataoka S, Watanabe A, Tabira T, Takahashi K, et al. Chronic cerebral hypoperfusion induced by right unilateral common carotid artery occlusion causes delayed white matter lesions and cognitive impairment in adult mice. Exp Neurol. 2008;210(2):585-91.
45. Driscoll CF, Morris RM, Senyei AE, Widder KJ, Heller GS. Magnetic targeting of microspheres in blood flow. Microvasc Res. 1984;27(3):353-69.
46. Chertok B, David AE, Yang VC. Magnetically-enabled and mr-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials. 2011;32(26):6245-53.
47. Chertok B, David AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials. 2010;31(24):6317-24.
48. Pulfer SK, Gallo JM. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J Drug Target. 1998;6(3):215-27.
49. Thorpe PE, Burrows FJ. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat. 1995;36(2):237-51.
50. Bandres E, Andion E, Escalada A, Honorato B, Catalan V, Cubedo E, et al. Gene expression profile induced by bcnu in human glioma cell lines with differential mgmt expression. J Neuro-Oncol. 2005;73(3):189-98.
51. McNeil PL, Murphy RF, Lanni F, Taylor DL. A method for incorporating macromolecules into adherent cells. J Cell Biol. 1984;98(4):1556-64.
52. Chakrabarti R, Wylie DE, Schuster SM. Transfer of monoclonal antibodies into mammalian cells by electroporation. J Biol Chem. 1989;264(26):15494-500.
53. Basu SK. Receptor-mediated endocytosis of macromolecular conjugates in selective drug delivery. Biochem Pharmacol. 1990;40(9):1941-6.
54. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285(5433):1569-72.
55. Huang Y, Shin Park Y, Wang J, Moon C, Min Kwon Y, Sun Chung H, et al. Attempts system: a macromolecular prodrug strategy for cancer drug delivery. Curr Pharm Des. 2010;16(21):2369-76.
56. Bagshawe KD. Antibody directed enzymes revive anti-cancer prodrugs concept. Brit J Cancer. 1987;56(5):531-2.
57. Syrigos KN, Epenetos AA. Antibody directed enzyme prodrug therapy (adept): a review of the experimental and clinical considerations. Anticancer Res. 1999;19(1A):605-13.
58. Liang JF, Li YT, Song H, Park YJ, Naik SS, Yang VC. Attempts: a heparin/protamine-based delivery system for enzyme drugs. J Control Release. 2002;78(1-3):67-79.
59. Doxorubicin hydrochloride. In: Ahfs drug information. Bethesda: American Hospital Formulary Service; 2001. p. 950-60.
60. Asparaginase. In: Ahfs drug information. Bethesda: American Hospital Formulary Service; 2001. p. 872-5.
61. Niesner U, Halin C, Lozzi L, Günthert M, Neri P, Wunderli-Allenspach H, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating hiv-1 tat peptides. Bioconjug Chem. 2002;13(4):729-36.
62. Pulfer SK, Ciccotto SL, Gallo JM. Distribution of small magnetic particles in brain tumor-bearing rats. J Neuro-Oncol. 1999;41(2):99-105.
63. McBain SC, Yiu HHP, El Haj A, Dobson J. Polyethyleneimine functionalized iron oxide nanoparticles as agents for DNA delivery and transfection. J Mater Chem. 2007;17(24):2561-5.
64. Park YJ, Liang JF, Ko KS, Kim SW, Yang VC. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. J Gene Med. 2003;5(8):700-11.
65. Futami J, Kitazoe M, Maeda T, Nukui E, Sakaguchi M, Kosaka J, et al. Intracellular delivery of proteins into mammalian living cells by polyethylenimine-cationization. J Biosci Bioeng. 2005;99(2):95-103.
66. Stivaktakis N, Nikou K, Panagi Z, Beletsi A, Leondiadis L, Avgoustakis K. Immune responses in mice of β-galactosidase adsorbed or encapsulated in poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J Biomed Mater Res A. 2005;73A(3):332-8.
67. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000;60(23):6641-8.
68. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am J Roentgenol. 1989;152(1):167-73.
69. Eckman WW, Patlak CS, Fenstermacher JD. A critical evaluation of the principles governing the advantages of intra-arterial infusions. J Pharmacokinet Biopharm. 1974;2(3):257-85.